Treatment of Hepatocellular Carcinoma Combining Sorafenib and Transarterial Locoregional Therapy: State of the Science
http://www.jvir.org/article/S1051-0443(13)00568-X/fulltext
Great article about combining 2 already widely utilized methods to treat HCC.
In short, TACE produces ischemia, upregulating VEGF, tumor angiogenesis.
Sorafenib is thought to work directly on VEGF receptors, inhibiting angiogenesis.
Is it worth some of the mentioned adverse events?
http://www.jvir.org/article/S1051-0443(13)00568-X/fulltext
Great article about combining 2 already widely utilized methods to treat HCC.
In short, TACE produces ischemia, upregulating VEGF, tumor angiogenesis.
Sorafenib is thought to work directly on VEGF receptors, inhibiting angiogenesis.
Is it worth some of the mentioned adverse events?